Page 21 - 《中国药房》2025年7期

的诊疗和救治水平不高，相关法律和医保政策有待出 prices in the 21st century[M]. Cham：Springer Interna‐
台。2018 年，《第一批罕见病目录》公布，界定了 121 种 tional Publishing，2015：1-23.
罕见病，打破了我国长久以来没有罕见病定义的僵局。 [ 8 ] STEWART D J，BRADFORD J P，SEHDEV S，et al. New
此外，澳大利亚等国还在PBS之外建立了LSDP、对 anticancer drugs：reliably assessing “value” while addres-
使用私立医疗机构的费用减免政策和商业保险体系等， sing high prices[J]. Curr Oncol，2024，31（5）：2453-2480.
[ 9 ] 杨姿锐，陶田甜，蒋蓉，等. 澳大利亚医保药品价格协议
覆盖了绝大部分医疗需求。我国可借鉴相关经验，进一
研究及对我国的启示[J]. 中国卫生经济，2020，39（6）：
步扩大医保目录覆盖范围，纳入更多罕见病和孤儿药，
93-96.
同时建立专项救助基金和商业保险补充机制；同时加强
[10] MANSFIELD S J. Generic drug prices and policy in
与国际相关部门合作，共享孤儿药研发技术和临床数
Australia：room for improvement? a comparative analysis
据，降低研发成本。此外，我国还可通过设立孤儿药专 with England [J]. Aust Health Rev，2014，38（1）：6-15.
项审批通道和补贴政策，促进国内外企业加大投入，解 [11] PBS. First new brand price reductions[EB/OL]. [2024-10-
决罕见病治疗的“无药可用”问题。 01]. https：//www.pbs.gov.au/info/industry/pricing/pbs-
3 结语 items/first-new-brand-price-reductions.
澳大利亚通过多部门协作、临床需求导向的新药注 [12] Australian Government Department of Health and Aged
册路径、科学的定价机制和全面的药品支持体系，确保 Care. What is price disclosure[EB/OL]. [2024-01-09]. https：//
了药品的公平可及，同时维护了医保的可持续性。这些 www. pbs. gov. au/info/industry/pricing/price-disclosure-
经验为我国深化“三医联动”改革、完善医保支付机制以 spd#_what_is_price.
及提升罕见病用药保障水平提供了参考。在当前我国 [13] Generic and Biosimilar Medicines Association. Price dis‐
closure[EB/OL]. [2024-10-26]. https：//gbma.com.au/price-
全面推进中国式现代化的大背景下，提升药品可及性不
disclosure/.
仅是健全医疗卫生体系的重要任务，更是实现“健康中
[14] LEE J，PANAGIOTELIS A，CAIRNS R，et al. An analysis
国”目标的关键环节。未来，通过借鉴国际先进经验，结合
of the trends in the usage of Pharmaceutical Benefits
我国国情深化医保统筹、优化新药审批路径、完善价格 Scheme-subsidised cancer drugs in Australia from 2012 to
谈判机制并加大政策支持力度，我国药品可及性水平必 2022[J]. J Cancer Res Clin Oncol，2024，150（8）：375.
将进一步提升，从而更好地满足人民群众的健康需求。 [15] JONES AM，SERRA-SASTRE V，KIM H. The impact of
参考文献 generic entry of pharmaceuticals in Australia[J]. Value
[ 1 ] Australian Government Department of Health and Aged Health Reg Issues，2024，43：101008.
Care. Pharmaceutical Benefits Scheme （PBS） expendi‐ [16] NG Q X，ONG C，CHAN K E，et al. Comparative policy
ture & prescriptions report （1 July 2022 to 30 June 2023） analysis of national rare disease funding policies in
[EB/OL]. [2024-08-12]. https：//www.PBS.gov.au/statistics/ Australia，Singapore，South Korea，the United Kingdom
expenditure-prescriptions/2022-2023/PBS-Expenditure- and the United States：a scoping review[J]. Health Econ
prescriptions-report-2022-23. Rev，2024，14（1）：42.
[ 2 ] Pharmaceutical Benefits Scheme. PBS News[EB/OL]. [17] RUSECKAITE R，MUDUNNA C，CARUSO M，et al.
[2024-08-12]. https：//www.pbs.gov.au/info/news/2024/ Current state of rare disease registries and databases in
05/pbs-website-update-1-may-2024. Australia：a scoping review[J].Orphanet J Rare Dis，2023，
[ 3 ] Pharmaceutical Benefits Scheme. PBS website update[EB/ 18（1）：216.
OL]. [2025-02-01]. https：//www. pbs. gov. au/info/news/ [18] Australian Government Department of Health and Aged
2025/02/pbs-website-update-1-february-2025. Care. About the life saving drugs program[EB/OL]. [2024-
[ 4 ] 李大双，颜建周，邵蓉. 澳大利亚PBS药品上市后再审查 09-02]. https：//www.health.gov.au/our-work/life-saving-
制度介绍及对我国的启示[J]. 中国药房，2023，34（15）： drugs-program/about-the-lsdp.
1793-1797. [19] Maven Marketing. List of pharmacies and chemists in
[ 5 ] Australian Therapeutics and Goods Administration. Australia[EB/OL]. [2024-08-22]. http：//www. mavenmar‐
Australian prescription medicines registration process[EB/ keting.com.au/list-of-pharmacies-in-australia.
OL]. [2024-08-12]. https：//www. tga. gov. au/prescription- [20] Australian Government Department of Health and Aged
medicines-registration-process. Care. Community pharmacy programs under the eighth
[ 6 ] YOFFE A，LIU J，SMITH G，et al. Regulatory reform out‐ community pharmacy agreement[EB/OL]. [2024-08-22].
comes and accelerated regulatory pathways for new pre‐ https：//www.health.gov.au/resources/collections/eighth-
scription medicines in Australia[J]. Ther Innov Regul Sci， community-pharmacy-agreement-fact-sheets.
2023，57（2）：271-286. （收稿日期：2024-10-29 修回日期：2025-02-21）
[ 7 ] VITRY A I，THAI L，ROUGHEAD E E. Pharmaceutical （编辑：刘明伟）

中国药房 2025年第36卷第7期 China Pharmacy 2025 Vol. 36 No. 7 · 783 ·